普萊柯(603566.SH)上半年淨利6507.68萬元同比降14.86%
格隆匯8月21日丨普萊柯(603566.SH)披露2019年半年度報告，報告期內公司實現營業收入3.20億元，同比增長12.02%；歸屬於上市公司股東的淨利潤6507.68萬元，同比下降14.86%；經營活動現金淨流入238.60萬元，同比下降94.63%；基本每股收益0.20元，加權平均淨資產收益率3.99%。
報告期末，公司總資產18.20億元，較上年度末減少4.34%；歸屬於上市公司股東的淨資產16.04億元，較上年度末1.92%。
公司持續以市場需求為導向，穩步推進一批重點經濟動物疫苗項目研發。針對口蹄疫(O型、A型)、禽流感(H5+H7亞型)等重大動物疫病，公司緊密跟蹤疫病發展趨勢，順應市場對於產品升級換代的需求，積極協調內、外部資源，組建高水平項目研發團隊，持續加大對相關基因工程疫苗的研發投入力度，確保上述研發項目的有序開展，為下一步申報臨牀試驗做好準備工作。
公司積極佈局寵物用動物保健產品，目前全力推動寵物疫苗、治療性生物製品、化學藥品的研發進程。在寵物疫苗開發方向，公司聯合中國獸醫藥品監察所開發的狂犬病滅活疫苗已進入新獸藥註冊階段，該產品具有安全、高效、免疫持續期長、產品保存期長等優勢；公司自主開發的犬瘟熱、犬細小二聯活疫苗的實驗室研究進展順利，正在積極準備申報臨牀試驗，該產品對低日齡犬安全性好，且能有效突破母源抗體干擾。在寵物化學藥品方向，公司開發的替米沙坦口服溶液、複方非潑羅尼滴劑等多項具有廣闊市場前景的抗感染類及驅蟲類藥物進入新獸藥註冊階段；公司自主開發的化學新結構萊柯黴素進展順利，主要應用於犬細菌性呼吸道疾病和支原體感染的治療，目前已完成中試研究，並取得國際發明專利授權。
公司各經營模塊的經營情況如下：在豬用疫苗方面，藉助偽狂犬基因工程滅活疫苗和圓-支二聯疫苗上市契機，通過組織架構調整、創新營銷模式等策略，積極開拓市場、尋找突破，與養豬產業共度難關，報告期，公司豬用疫苗實現銷售收入5405.74萬元，較去年同期下降40.11%。在禽用疫苗方面，抓住禽用疫苗良好的市場機遇期，持續推廣“434”系列免疫方案、新流法1日齡免疫等科學減負方案，切實為用户創造價值，大幅提升公司業績，報告期，禽用疫苗及抗體實現銷售收入1.44億元，較去年同期增長38.76%。在化學藥品方面，抓住非洲豬瘟疫情對消毒劑市場的需求，同時通過強化大單品營銷、集團客户開發、中獸藥製劑的推廣等措施，實現營業收入1.05億元，較去年同期增長30.47%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
